Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life

Stanislas Pol, Marion Corouge, Anaïs Vallet-Pichard Université Paris Descartes, Liver Department, Assistance Publique Hôpitaux de Paris, Cochin Hospital, French Institute of Health and Medical Research UMS20, Institut Pasteur, Paris, France Abstract: The treatment of h...

Full description

Bibliographic Details
Main Authors: Pol S, Corouge M, Vallet-Pichard A
Format: Article
Language:English
Published: Dove Medical Press 2016-03-01
Series:Hepatic Medicine: Evidence and Research
Subjects:
Hepatitis C virus/Direct acting antivirals/Sofosbuvir/Daclatasvir
Online Access:https://www.dovepress.com/daclatasvirndashsofosbuvir-combination-therapy-with-or-without-ribavir-peer-reviewed-article-HMER

Internet

https://www.dovepress.com/daclatasvirndashsofosbuvir-combination-therapy-with-or-without-ribavir-peer-reviewed-article-HMER

Similar Items